跳至主要内容
临床试验/CTRI/2021/07/034990
CTRI/2021/07/034990
尚未招募
2 期

Primary Surgery versus Primary Chemoradiation for Oropharyngeal Cancer (SCOPe trial) â??A Phase II/III Integrated Design Randomized Control Trial. - SCOPe

Tata Memorial Centre0 个研究点目标入组 0 人待定

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
Tata Memorial Centre
状态
尚未招募
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional

研究者

入排标准

入选标准

  • Histopathology proven diagnosis of squamous cell carcinoma of the oropharynx, localized to the tonsil and /or lateralized tongue\-base
  • 2\. ECOG Performance Status \<\=2
  • 3\. Age \>\=18 to 70 years
  • 4\. Anesthetic fitness obtained for surgery under general anesthesia
  • 5\. Resectable primary tumor with an anticipation of achieving resection free margins either by minimally invasive/open techniques
  • 6\. Clinical stage III or IV, i.e. T1 T2 or T3 \-T4 with N0\-N3\.
  • Nodal disease with extranodal extension on clinical examination/
  • imaging may be included at the surgeonâ??s discretion, if the nodal disease is deemed resectable by the operating surgeon
  • 7\. HPV negative status determined by p16 status
  • 8\. No distant metastases below the clavicles, based upon the following minimum

排除标准

  • 1\. Prior head and neck malignancy
  • 2\. Prior invasive malignancy, unless disease free for a minimum of 3 years
  • 3\. Prior chemotherapy for a different cancer administered
  • within 3 years prior to registration
  • 4\. Patients who have received any neoadjuvant/ induction chemotherapy
  • 5\. Prior radiotherapy to the region of the head and neck that would result in overlap of radiation therapy fields
  • 6\. Unresectable primary or nodal disease involving the carotid vessels, prevertebral fascia or skull base
  • 7\. Large soft palate involvement \>1 cm 8\. Deep extension into larynx,
  • pre\-epiglottic space and deep invasion into extrinsic
  • muscles of tongue

结局指标

主要结局

未指定

相似试验